A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study.
Lung CancerAug 13, 2026 (epub)
Huaqiang Zhou, Qing Zhou, Qisen Guo et al.
✦ AI-curated · Sources linked
In 30 seconds
The OCEAN II study, a phase 2 clinical trial, evaluated the efficacy and safety of encorafenib combined with binimetinib in 63 Chinese participants with BRAF V600E-mutated metastatic non-small cell lung cancer. The confirmed objective response rate was 59% (95% CI 45-72), indicating significant clinical benefit in this population.
Key findings
- Confirmed objective response rate was 59% (95% CI 45-72) in the main analysis.
- Disease control rate reached 87% (95% CI 75-95).
- Median overall survival was 27.9 months (14.7-30.0).
- 98.4% of participants experienced at least one treatment-related adverse event.
Why it matters
The study highlights the potential of encorafenib and binimetinib as effective treatment options for a specific subset of lung cancer patients, addressing a critical need in managing BRAF V600E-mutated metastatic non-small cell lung cancer.